Pharma giants Bayer and Theramex say current frameworks disincentivise companies from submitting new HRT and MHT products to the PBAC.
Pharma giants Bayer and Theramex say current frameworks disincentivise companies from submitting new HRT and MHT products to the PBAC.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.